dendritic cell vaccine (National Cancer Institute)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namedendritic cell vaccine (National Cancer Institute)

Drug Alias Namemutant p53 peptide pulsed dendritic cell vaccine (National Cancer Institute)

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccineCell and gene therapy > Cell therapy

Mechanisms of ActionTumor protein p53 modulators

TargetsTumor protein p53

Therapy Area/IndicationsHead and Neck NeoplasmsCarcinoma, Squamous Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Cancer Institute

Active IndicationsN/A

Inactive IndicationsHead and Neck NeoplasmsCarcinoma, Squamous Cell

Other Information

ATC CodeN/A